The Life Sciences team advised Seagen Inc. in its multi-year, multi-target strategic collaboration agreement with Nurix Therapeutics, Inc. to advance a new class of medicines called Degrader-Antibody Conjugates for use in cancer.
Under the terms of the agreement, Nurix will receive an upfront payment of $60 million and has the potential to receive up to approximately $3.4 billion in research, development, regulatory and commercial milestone payments across multiple programs.
Seagen, a pioneer in the field of antibody-drug conjugates (ADCs), is a global biotechnology company that discovers, develops, manufactures and commercializes targeted cancer therapeutics.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases.
The Goodwin team was led by Adam Bellack, with invaluable support from Susan Lee, Jin Paul, Barry Bazian, Robby Frederickson, Julia White, Bradley Weber, Sam Beavers, and Daniela Sanchez.
For more details, read Nurix’s press release and articles in BioPharma Dive, BioSpace, BioWorld, Endpoints News, Fierce Biotech and MedCity News.